Showing results (241-250 of 366) with videos related to

Sort By:
Pageof 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2025
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III TrialEnriqueta Felip, Nasser Altorki, Caicun Zhou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 5, 2023
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized StudyEverett E Vokes, Francoise Mornex, Ahmet Sezer, et al.
European Journal of Cancer (Oxford, England : 1990)|July 10, 2022
Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label studyDaniel S W Tan, Sang-We Kim, Santiago Ponce Aix, et al.
JAMA Oncology|June 15, 2018
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical TrialGlenwood D Goss, Enriqueta Felip, Manuel Cobo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2019
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung CancerAlice T Shaw, Benjamin J Solomon, Benjamin Besse, et al.
European Journal of Cancer (Oxford, England : 1990)|September 13, 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trialMartin Reck, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2025
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trialAnne-Marie C Dingemans, Konstantinos Syrigos, Lorenzo Livi, et al.
Alimentary Pharmacology & Therapeutics|February 8, 2024
An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injuryMar Riveiro-Barciela, Ana Barreira-Díaz, María-Teresa Salcedo, et al.
Lancet (London, England)|December 30, 2015
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialRoy S Herbst, Paul Baas, Dong-Wan Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 StudyMarina C Garassino, Shirish Gadgeel, Giovanna Speranza, et al.
Pageof 37